Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
McKesson
Colorcon
Moodys

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR VIREAD


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Viread

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00051831 ↗ Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults Completed AIDS Clinical Trials Group N/A 2003-10-01 HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
NCT00051831 ↗ Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2003-10-01 HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
NCT00074581 ↗ Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed HIV Prevention Trials Network Phase 3 2005-02-01 This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Viread

Condition Name

Condition Name for Viread
Intervention Trials
Chronic Hepatitis B 21
Hepatitis B 15
HIV Infections 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Viread
Intervention Trials
Hepatitis 54
Hepatitis B 52
Hepatitis A 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Viread

Trials by Country

Trials by Country for Viread
Location Trials
United States 169
Korea, Republic of 24
Thailand 14
Canada 12
China 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Viread
Location Trials
California 18
New York 13
North Carolina 9
Massachusetts 9
Texas 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Viread

Clinical Trial Phase

Clinical Trial Phase for Viread
Clinical Trial Phase Trials
Phase 4 25
Phase 3 14
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Viread
Clinical Trial Phase Trials
Completed 51
Unknown status 14
Recruiting 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Viread

Sponsor Name

Sponsor Name for Viread
Sponsor Trials
Gilead Sciences 14
Third Affiliated Hospital, Sun Yat-Sen University 8
National Institute of Allergy and Infectious Diseases (NIAID) 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Viread
Sponsor Trials
Other 129
Industry 51
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Baxter
Boehringer Ingelheim
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.